meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced NSCLC - (neo)adjuvant (NA)
1
laNSCLC - NA - all population
HER inhibitor
EGFR inhibitor
erlotinib based treatment
erlotinib alone
gefitinib based treatment
gefitinib alone
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab plus SoC
no study with result for this clinical condition